Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Show more...
FAQ
Moberg Pharma AB 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 Boerse Muenchen 交易所,Moberg Pharma AB 的股票以代號 MB8A.MU 進行交易。
Moberg Pharma AB 下一次財報日期是什麼時候?▼
Moberg Pharma AB 將於 August 13, 2026 公布下一次財報。
Moberg Pharma AB 去年的營收是多少?▼
Moberg Pharma AB 去年的營收為 1.23MEUR。
Moberg Pharma AB 去年的淨利是多少?▼
MB8A.MU 去年的淨收益為 -2.49MEUR。
Moberg Pharma AB 有多少名員工?▼
截至 July 10, 2026,公司共有 11 名員工。
Moberg Pharma AB 位於哪個產業?▼
Moberg Pharma AB從事於Other產業。
Moberg Pharma AB 何時完成拆股?▼
Moberg Pharma AB 最近沒有進行任何拆股。
Moberg Pharma AB 的總部在哪裡?▼
Moberg Pharma AB 的總部位於 瑞典 的 Bromma。